Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 277-749-7 | CAS number: 74181-84-3
One chronic study is available with EDTA-CaNa2 in rats, and two supporting chronic studies are available with EDTA-Na3H in rats and mice, respectively (see also read across document in section 13).
No treatment-related tumours were observed following chronic exposure to either EDTA-CaNa2 or EDTA-Na3H. In addition, other chelates did not demonstrate any pre-neoplastic or neoplastic lesions in repeated dose toxicity studies.
Justification for selection of carcinogenicity via oral route endpoint:
See also read across document in section 13.
Because no treatment-related tumours have been observed following chronic exposure to EDTA-CaNa2, and no treatment-related tumours have been observed following chronic exposure to EDTA-Na3H, and no such effects are expected for EDTA-CuK2, this substance does not need classification for this endpoint.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Close Do not show this message again